Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

被引:29
作者
Birk, M
Svedhem, V
Sönnerborg, A
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden
[3] Karolinska Hosp, Div Infect Dis, S-10401 Stockholm, Sweden
关键词
antiretroviral therapy; drug resistance; HIV-1; rebound; viral load;
D O I
10.1097/00002030-200107270-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the kinetics of HIV-1 RNA and drug-induced mutations after cessation of anti retroviral therapy (ART). Design and methods: Successive plasma samples from 26 patients were tested for HIV-1 RNA by PCR and for mutations associated with drug resistance by sequencing of the pol gene. Results: After cessation of ART the phase of undetectable virus (< 50 copies/ml), ranging from 6 to more than 29 days, was followed by a rapid viral increase, which slowed down before a plateau corresponding to pre-treatment levels or higher was reached in most cases (14/19 patients). In one patient virus was still undetectable at 4 weeks. Also, a significantly larger number of primary protease inhibitor (PI)-associated mutations reverted to wild-type, as compared with secondary PI-, and primary reverse transcriptase inhibitor (RTI)-associated mutations. During the rapid viral increase no mutations disappeared, which instead happened during the slower viral increase preceding the viral plateau level. Conclusion: After discontinuation of ART large individual Variations were found for the time period until HIV-1 became detectable in plasma, possibly due to differences in the HIV-1 specific immunity. The more rapid loss of primary PI mutations suggests that they might cause a more impaired viral fitness than primary RTI mutations. However, the persistence of drug mutations during the initial viral load increase indicates that mutated strains may still replicate efficiently (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1359 / 1368
页数:10
相关论文
共 36 条
[31]   HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [J].
Pitcher, CJ ;
Quittner, C ;
Peterson, DM ;
Connors, M ;
Koup, RA ;
Maino, VC ;
Picker, LJ .
NATURE MEDICINE, 1999, 5 (05) :518-525
[32]   Immune control of HIV-1 after early treatment of acute infection [J].
Rosenberg, ES ;
Altfeld, M ;
Poon, SH ;
Phillips, MN ;
Wilkes, BM ;
Eldridge, RL ;
Robbins, GK ;
D'Aquila, RT ;
Goulder, PJR ;
Walker, BD .
NATURE, 2000, 407 (6803) :523-526
[33]   LONG-TERM PERSISTENCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN PLASMA ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 OF DIDEOXYINOSINE-TREATED PATIENTS REMOVED FROM ZIDOVUDINE THERAPY [J].
SMITH, MS ;
KOERBER, KL ;
PAGANO, JS .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) :184-188
[34]   Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype [J].
Verhofstede, C ;
Van Wanzeele, F ;
Van der Gucht, B ;
De Cabooter, N ;
Plum, J .
AIDS, 1999, 13 (18) :2541-2546
[35]   Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens [J].
Youle, M ;
Janossy, G ;
Turnbull, W ;
Tilling, R ;
Loveday, C ;
Mocroft, A ;
Tyrer, M ;
Madge, S ;
Wilson, D ;
Dykhoff, A ;
Johnson, M ;
Phillips, AN .
AIDS, 2000, 14 (12) :1717-1720
[36]   Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites [J].
Zhang, YM ;
Imamichi, H ;
Imamichi, T ;
Lane, HC ;
Falloon, J ;
Vasudevachari, MB ;
Salzman, NP .
JOURNAL OF VIROLOGY, 1997, 71 (09) :6662-6670